While checkpoint inhibitors represent a class of promising new therapies to treat cancer, the efficacy of these immunotherapies have been limited because of the ability of cancers to develop resistance. In part, that’s because of the multiple mechanisms cancers have to evade the immune system. Compugen is using a computational discovery platform to identify proteins and pathways that drive immune resistance mechanisms to checkpoint inhibitors. We spoke to Anat Cohen-Dayag, CEO of Compugen, about the company’s discovery platform, its efforts to develop new treatments that address patients who don’t respond to current checkpoint inhibitors, and its clinical pipeline in development.
Learn More